-
Confronting the financial burdens of DMD with a heap of faith
I have seven children, and three of them are living with Duchenne muscular dystrophy (DMD):
-
Why having my own ‘escape hatch’ is key to my happiness
Roughly four decades into living with limb-girdle muscular dystrophy, I’ve developed numerous ways to thrive.
-
Del-zota increases dystrophin in DMD patients, new trial data show
Avidity Biosciences‘ delpacibart zotadirsen, or del-zota for short — formerly called AOC 1044 — was
-
Ladies Luncheon Newport Beach to Debut at Shady Canyon Golf Club on October 15 Benefiting CureDuchenne Inaugural Event Features Fashion, Food, and Fun to Raise Funds for Cutting-Edge Duchenne Muscular Dystrophy Research
NEWPORT BEACH, California (August 13, 2024) – CureDuchenne, a global nonprofit dedicated to funding and
-
Adjusting my definition of what it means to be a man
Kevin Schaefer, the associate director of community content at Bionews, the parent company of this
-
SAT-3247 for DMD wins FDA rare pediatric disease designation
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to SAT-3247,
-
Finding Support to Manage Behaviors in Duchenne and Becker
Research has shown that dystrophin is usually present in the brain as well as in
-
Solid Biosciences has begun dosing patients in their clinical study of their next-generation gene therapy, SGT-003 for those living with Duchenne.
Letter to the Duchenne Community – INSPIRE DUCHENNE update Dear Duchenne Community, We are writing
-
PPMD Urges FDA to Conduct a Full Review of Ataluren (Translarna) Following Resubmission of NDA
PTC Therapeutics has shared that it has resubmitted its New Drug Application (NDA) to the
-
Avidity Biosciences Announces Positive Data From Phase 1/2 EXPLORE44™ Trial of AOC 1044 in Individuals Amenable to Exon 44 Skipping
Avidity Biosciences, Inc. today announced positive data from the company’s Phase 1/2 EXPLORE44 clinical trial
